For an adolescent with major depression treated with SSRIs, which adjunct therapy provides protective effect against suicide risk?

For an adolescent with major depression treated with SSRIs, which adjunct therapy provides protective effect against suicide risk?

• A. Addition of risperidone therapy
• B. Cognitive-behavioral therapy
• C. Family therapy
• D. Hospitalization

Answer: (B)

The key idea is that adding a structured psychotherapy to antidepressant treatment can significantly reduce suicide risk in depressed adolescents. Cognitive-behavioral therapy helps by teaching skills to identify and challenge negative thoughts, manage intense emotions, and solve problems effectively. It also incorporates safety planning, recognition of warning signs, and steps to seek help when distress rises, which are crucial in adolescence where suicidal urges can flare quickly. When used alongside SSRIs, CBT has strong evidence showing reductions in both suicidal ideation and attempts, offering a protective effect beyond medication alone. Other options don’t provide this targeted, ongoing impact in the same way. Hospitalization is reserved for acute danger and doesn’t function as a preventive adjunct for the broader risk over time. Adding risperidone may help certain symptoms or be used for treatment-resistant cases, but it isn’t consistently shown to lower suicide risk. Family therapy can improve support and communication, which is beneficial, but CBT’s focus on changing cognitive patterns and equipping the patient with concrete skills has the strongest evidence for reducing suicide risk in this context. So, cognitive-behavioral therapy is the adjunct most protective against suicide risk when treating an adolescent with major depression on SSRIs.

The key idea is that adding a structured psychotherapy to antidepressant treatment can significantly reduce suicide risk in depressed adolescents. Cognitive-behavioral therapy helps by teaching skills to identify and challenge negative thoughts, manage intense emotions, and solve problems effectively. It also incorporates safety planning, recognition of warning signs, and steps to seek help when distress rises, which are crucial in adolescence where suicidal urges can flare quickly. When used alongside SSRIs, CBT has strong evidence showing reductions in both suicidal ideation and attempts, offering a protective effect beyond medication alone.

Other options don’t provide this targeted, ongoing impact in the same way. Hospitalization is reserved for acute danger and doesn’t function as a preventive adjunct for the broader risk over time. Adding risperidone may help certain symptoms or be used for treatment-resistant cases, but it isn’t consistently shown to lower suicide risk. Family therapy can improve support and communication, which is beneficial, but CBT’s focus on changing cognitive patterns and equipping the patient with concrete skills has the strongest evidence for reducing suicide risk in this context.

So, cognitive-behavioral therapy is the adjunct most protective against suicide risk when treating an adolescent with major depression on SSRIs.